IMMULITE® Third Generation PSA Cleared for U.S.

DPC has received FDA clearance to market in the US its IMMULITE Third Generation PSA assay, an ultrasensitive method to aid in the management of prostate cancer patients. IMMULITE Third Generation PSA has a detection limit (defined as the concentration 2 SD above the response at zero dose) of 0.003 ng/mL. Thomas A. Stamey, M.D., Professor of Urology at Stanford Medical Center, has remarked that the IMMULITE Third Generation PSA assay is "the most sensitive assay to date to be put on the market." He added, "The assay's ultrasensitivity is a tremendous advantage in monitoring cancer patients, allowing clinicians an important time advantage in which to assess and treat patients. Also, the results gained through this assay can be reassuring to patients, who are understandably concerned whether their cancer has been successfully treated."

IMMULITE Third Generation PSA is available in kit sizes of 100 and 500 tests. For further information on the assay or the IMMULITE system, contact your local DPC representative or your National Distributor.